+

WO2006063864A3 - Compositions de prevention, de reduction ou de traitement d'une inflammation induite par keratinocytes - Google Patents

Compositions de prevention, de reduction ou de traitement d'une inflammation induite par keratinocytes Download PDF

Info

Publication number
WO2006063864A3
WO2006063864A3 PCT/EP2005/014198 EP2005014198W WO2006063864A3 WO 2006063864 A3 WO2006063864 A3 WO 2006063864A3 EP 2005014198 W EP2005014198 W EP 2005014198W WO 2006063864 A3 WO2006063864 A3 WO 2006063864A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
preventing
reducing
osmrβ
subunit
Prior art date
Application number
PCT/EP2005/014198
Other languages
English (en)
Other versions
WO2006063864A2 (fr
Inventor
Jean-Claude Lecron
Hugues Gascan
Franck Morel
Sylvie Chevalier
Francois-Xavier Bernard
Katia Boniface
Caroline Diveu
Original Assignee
Univ Angers
Univ Poitiers
Bioalternatives Sas
Jean-Claude Lecron
Hugues Gascan
Franck Morel
Sylvie Chevalier
Francois-Xavier Bernard
Katia Boniface
Caroline Diveu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Angers, Univ Poitiers, Bioalternatives Sas, Jean-Claude Lecron, Hugues Gascan, Franck Morel, Sylvie Chevalier, Francois-Xavier Bernard, Katia Boniface, Caroline Diveu filed Critical Univ Angers
Priority to EP05824336.1A priority Critical patent/EP1827485B1/fr
Priority to CA2589670A priority patent/CA2589670C/fr
Priority to US11/721,763 priority patent/US20090300776A1/en
Publication of WO2006063864A2 publication Critical patent/WO2006063864A2/fr
Publication of WO2006063864A3 publication Critical patent/WO2006063864A3/fr
Priority to US13/283,508 priority patent/US20120142755A1/en
Priority to US14/500,373 priority patent/US10080779B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention se rapporte au domaine de la réparation épidermique. L'invention concerne plus particulièrement l'utilisation d'une molécule apte à inhiber un récepteur hétéromère comprenant OSMRβ comme sous-unité pour la préparation d'une composition permettant d'inhiber l'expression de facteurs inflammatoires au moyen des kératinocytes. L'invention concerne en particulier l'utilisation d'antagonistes et/ou d'inhibiteurs d'expression de OSM, IL-17, TNFa, IL-31, IFN-η, et/ou la sous-unité OSMRβ en vue de la préparation de compositions cosmétiques ou dermatologiques, notamment pour le traitement de maladies cutanées inflammatoires. L'invention concerne en outre des procédés d'obtention in vitro ou de modèles animaux de maladies inflammatoires cutanées. Ces modèles peuvent être utilisés pour dépister des molécules afin de trouver de nouveaux médicaments de prévention ou de traitement du psoriasis et d'autres dermatites.
PCT/EP2005/014198 2004-12-15 2005-12-15 Compositions de prevention, de reduction ou de traitement d'une inflammation induite par keratinocytes WO2006063864A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05824336.1A EP1827485B1 (fr) 2004-12-15 2005-12-15 Compositions de prevention, de reduction ou de traitement d'une inflammation induite par keratinocytes
CA2589670A CA2589670C (fr) 2004-12-15 2005-12-15 Compositions de prevention, de reduction ou de traitement d'une inflammation induite par keratinocytes
US11/721,763 US20090300776A1 (en) 2004-12-15 2005-12-15 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation
US13/283,508 US20120142755A1 (en) 2004-12-15 2011-10-27 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation
US14/500,373 US10080779B2 (en) 2004-12-15 2014-09-29 Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04293004.0 2004-12-15
EP04293004A EP1671642A1 (fr) 2004-12-15 2004-12-15 Composés contenant des (ant)agonistes de l'oncostatin M (OSM), IL-31 et IFN-gamma pour moduler la migration et fonction de keratinocytes au moyen d'un recepteur comprenant l'OSMRbeta comme sousunité, et applications correspondantes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/721,763 A-371-Of-International US20090300776A1 (en) 2004-12-15 2005-12-15 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation
US13/283,508 Division US20120142755A1 (en) 2004-12-15 2011-10-27 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation

Publications (2)

Publication Number Publication Date
WO2006063864A2 WO2006063864A2 (fr) 2006-06-22
WO2006063864A3 true WO2006063864A3 (fr) 2006-08-24

Family

ID=34931608

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/014198 WO2006063864A2 (fr) 2004-12-15 2005-12-15 Compositions de prevention, de reduction ou de traitement d'une inflammation induite par keratinocytes
PCT/EP2005/014199 WO2006063865A2 (fr) 2004-12-15 2005-12-15 Compositions d'amelioration de la migration de keratinocytes et pour la reparation epidermique au moyen d'un recepteur contenant osmrbêta comme sous-unite et leurs applications

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/014199 WO2006063865A2 (fr) 2004-12-15 2005-12-15 Compositions d'amelioration de la migration de keratinocytes et pour la reparation epidermique au moyen d'un recepteur contenant osmrbêta comme sous-unite et leurs applications

Country Status (5)

Country Link
US (3) US20090300776A1 (fr)
EP (3) EP1671642A1 (fr)
JP (1) JP5275630B2 (fr)
CA (2) CA2589670C (fr)
WO (2) WO2006063864A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339843T3 (es) 1999-06-02 2010-05-26 Chugai Seiyaku Kabushiki Kaisha Proteina receptora de hematopoyetina novedosa, nr10.
EP1221482B1 (fr) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Proteine receptrice d'hemopoietine (nr12)
RU2511406C2 (ru) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
RU2541780C2 (ru) 2007-12-05 2015-02-20 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
CA2840403A1 (fr) 2011-06-27 2013-01-03 Galderma Research & Development Nouveaux marqueurs de differenciation des th17 pour l'acne et leurs utilisations
US20140221648A1 (en) * 2011-06-27 2014-08-07 Galderma Research & Developement Th17 differentiation markers for acne and uses thereof
EP2809660B1 (fr) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Composés macrocycliques pour une modulation d'il-17
FR2993282B1 (fr) 2012-07-13 2017-11-10 Expanscience Lab Procede d'identification de marqueurs moleculaires de la peau d'enfant
FR3011008B1 (fr) 2013-09-24 2017-12-29 Expanscience Lab Procedes d'evaluation des effets deleteres des uv sur la peau d'enfant
FR3016373B1 (fr) 2014-01-10 2018-01-19 Laboratoires Expanscience Modele de peau de mammelon reconstitue
EP3119382B1 (fr) 2014-03-18 2020-03-25 Greenpharma Applications cosmetiques et pharmaceutiques de la vescalagine et de la castalagine
FR3019186B1 (fr) 2014-03-31 2019-06-07 Laboratoires Expanscience Procedes d'evaluation des effets deleteres de l'urine sur la peau d'enfant
EP3974450A3 (fr) 2015-01-29 2022-06-22 Oxford University Innovation Limited Biomarqueur
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
TW202327654A (zh) 2015-04-14 2023-07-16 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
US9867827B1 (en) * 2015-08-27 2018-01-16 Florida A&M University Methods and formulations for topical treatment of psoriasis
FR3045669B1 (fr) 2015-12-16 2019-04-05 Laboratoires Expanscience Procedes d'evaluation des effets de la deshydratation sur la peau d'enfant
FR3053053B1 (fr) 2016-06-23 2018-07-13 Laboratoires Expanscience Modeles de la dermatite atopique juvenile
WO2018156180A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
FR3068045B1 (fr) 2017-06-22 2021-06-04 Expanscience Lab Modeles de peau sensible reconstituee
EP4062933A4 (fr) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Préparation pharmaceutique comprenant un anticorps
US20230391878A1 (en) 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
TW202221039A (zh) 2020-10-19 2022-06-01 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
FR3133198A1 (fr) 2022-03-04 2023-09-08 Pierre Fabre Dermo-Cosmetique Modele de peau reconstituee
FR3138149A1 (fr) 2022-07-25 2024-01-26 Pierre Fabre Dermo-Cosmetique Méthode d’évaluation in vitro de l’activité photoprotectrice d’un actif

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744442A (en) * 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
WO2001037874A2 (fr) * 1999-11-24 2001-05-31 Centocor, Inc. Traitement du psoriasis
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA909842B (en) * 1989-12-08 1991-09-25 Oncogen Proteins with oncostatin m activity and process for their preparation
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US20060083713A1 (en) * 2000-10-13 2006-04-20 Eli Lilly And Company Methods of using a human il-17 related polypeptide to treat disease
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
EP1761643A1 (fr) * 2004-05-03 2007-03-14 Schering Corporation Utilisation de l'expression d'il-17 pour predire une inflammation cutanee et methodes de traitement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744442A (en) * 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
WO2001037874A2 (fr) * 1999-11-24 2001-05-31 Centocor, Inc. Traitement du psoriasis

Also Published As

Publication number Publication date
US7901669B2 (en) 2011-03-08
WO2006063864A2 (fr) 2006-06-22
JP5275630B2 (ja) 2013-08-28
WO2006063865A3 (fr) 2006-10-12
CA2589670C (fr) 2016-11-29
EP1830874B1 (fr) 2013-03-13
CA2590095A1 (fr) 2006-06-22
EP1827485A2 (fr) 2007-09-05
EP1671642A1 (fr) 2006-06-21
US20120142755A1 (en) 2012-06-07
CA2589670A1 (fr) 2006-06-22
US20090300776A1 (en) 2009-12-03
US20090104146A1 (en) 2009-04-23
EP1827485B1 (fr) 2013-12-18
JP2008524155A (ja) 2008-07-10
CA2590095C (fr) 2014-12-09
WO2006063865A2 (fr) 2006-06-22
EP1830874A2 (fr) 2007-09-12

Similar Documents

Publication Publication Date Title
WO2006063864A3 (fr) Compositions de prevention, de reduction ou de traitement d'une inflammation induite par keratinocytes
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008089307A3 (fr) Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
WO2008100328A3 (fr) Procédés et compositions de ciblage de la protéine gc1qr/p32
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2010001535A (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa.
WO2009109613A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2009151598A8 (fr) Diazacarbazoles et procédés d’utilisation
MX2007016462A (es) Composiciones topicas para tratar la piel.
WO2008115974A3 (fr) Analogues de pyrazolopyrimidine et leur utilisation en tant qu'inhibiteurs de kinase mtor et kinase pi3
HK1131167A1 (zh) 淚液脂質運載蛋白的突變蛋白及其獲得方法
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
WO2008116157A3 (fr) Cellules souches mésenchymateuses et leur utilisation
WO2009091550A8 (fr) Dérivés de 2,3-dihydroimidazo [1,2-c] quinazoline à substitution sulfone utilisés pour traiter des troubles hyperproliférants et des maladies associées à l'angiogénèse
UA84930C2 (ru) Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
EP2513343A4 (fr) Procédés et compositions pour traiter l'inflammation de la peau
WO2009147201A3 (fr) Agents anti-inflammatoires
WO2009109616A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40
WO2007046097A3 (fr) Compositions topiques pour le traitement ou la prevention de l'irritation cutanee provoquee par l'epilation
WO2006117465A3 (fr) Utilisation de polyphenols de cacao pour reguler la pigmentation de la peau
WO2009150408A3 (fr) Formulations antimuscariniques topiques
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2589670

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005824336

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005824336

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11721763

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载